Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jhanelle Gray

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
NPJ Precision Oncology|January 12, 2026
Predicting anti-PD-1 immune checkpoint blockade response in melanoma patients with spatially aware machine learning modelsAlyssa Pybus, Raphael Kirchgaessner, Jonathan Nguyen, et al.
Patterns (New York, N.Y.)|July 18, 2022
Mistic: An open-source multiplexed image t-SNE viewerSandhya Prabhakaran, Chandler Gatenbee, Mark Robertson-Tessi, et al.
Cancers|December 1, 2020
Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of ResponseSaurabh K Garg, Eric A Welsh, Bin Fang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancerEric B Haura, Tawee Tanvetyanon, Alberto Chiappori, et al.
International Journal of Radiation Oncology, Biology, Physics|September 14, 2014
Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancerThomas J Dilling, Martine Extermann, Jongphil Kim, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Pharmacokinetic Acceleration via CYP3A4 Hyperactivation as a Clinically Actionable Mechanism of Targeted Therapy Resistance in NSCLCPragya Kumar, Menkara Henry, Julia Pelesko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancerGerold Bepler, Charles Williams, Michael J Schell, et al.
Journal of Oncology Practice|October 30, 2014
Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year IntervalPaul B Jacobsen, Ji-Hyun Lee, William Fulp, et al.
Research Square|July 3, 2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 StudyEziafa Oduah, Jhanelle Gray, Thomas Stinchcombe, et al.
Immunotherapy|April 21, 2021
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)Jacob M Sands, Sumithra J Mandrekar, David Kozono, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
NPJ Precision Oncology|January 12, 2026
Predicting anti-PD-1 immune checkpoint blockade response in melanoma patients with spatially aware machine learning modelsAlyssa Pybus, Raphael Kirchgaessner, Jonathan Nguyen, et al.
Patterns (New York, N.Y.)|July 18, 2022
Mistic: An open-source multiplexed image t-SNE viewerSandhya Prabhakaran, Chandler Gatenbee, Mark Robertson-Tessi, et al.
Cancers|December 1, 2020
Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of ResponseSaurabh K Garg, Eric A Welsh, Bin Fang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancerEric B Haura, Tawee Tanvetyanon, Alberto Chiappori, et al.
International Journal of Radiation Oncology, Biology, Physics|September 14, 2014
Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancerThomas J Dilling, Martine Extermann, Jongphil Kim, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Pharmacokinetic Acceleration via CYP3A4 Hyperactivation as a Clinically Actionable Mechanism of Targeted Therapy Resistance in NSCLCPragya Kumar, Menkara Henry, Julia Pelesko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancerGerold Bepler, Charles Williams, Michael J Schell, et al.
Journal of Oncology Practice|October 30, 2014
Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year IntervalPaul B Jacobsen, Ji-Hyun Lee, William Fulp, et al.
Research Square|July 3, 2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 StudyEziafa Oduah, Jhanelle Gray, Thomas Stinchcombe, et al.
Immunotherapy|April 21, 2021
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)Jacob M Sands, Sumithra J Mandrekar, David Kozono, et al.
Pageof 3